top of page

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY DURING THE COVID-19 PANDEMIC PUBLISHED IN RED JOURNAL


July 15, 2020

Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194855/?report=reader

9 views

Recent Posts

See All

HNCIG-6/NRG HN002 RESULTS PUBLISHED IN JCO

January 28, 2021 This randomized phase II trial for good-risk HPV-associated OPSCC compared reduced-dose radiation (60 Gy) with or without concurrent weekly cisplatin. The RT-only arm was accelerated

bottom of page